Covid-19: Hamdard Labs to begin clinical trials of immunity-boosting drugs Infuza, Kulzam

Published On 2020-09-08 06:49 GMT   |   Update On 2020-09-08 06:49 GMT
Advertisement

New Delhi: Health and wellness firm Hamdard Laboratories on Monday said it is going to start a clinical trial of its two immunity boosting medicines to assess their effectiveness in preventing COVID-19 infection. The company has received all the regulatory approvals to begin the proof of concept clinical trial for its Infuza and Kulzam drugs, Hamdard Laboratories said in a statement.

A research team from Hamdard Institute of Medical Sciences and Research (HIMSR) is going to start the clinical trial at HAH Centenary Hospital in New Delhi, it added.
Advertisement
"A research group of HIMSR, that comprises an allopathic doctor, unani hakim, microbiologist and biochemist is working on a randomised, parallel group clinical trial for the repurposing of two popular Hamdard medicines i.e. Infuza and Kulzum for the prevention of COVID-19 infection," Hamdard Laboratories India (Medicine Division) Executive Trustee Asad Mueed said.
HIMSR and associated HAH Centenary Hospital CEO G N Qazi said: "We are going to start the clinical trial...to evaluate the efficacy of these drugs for the prevention of COVID-19 infection in high risk subjects."
The study concept is approved by the Special Project Approval Committee, Ministry of AYUSH and has also been cleared by the Institutional Ethics Committee of the hospital, he added.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News